{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:25:03Z","timestamp":1795040703256,"version":"4.10.2"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["R35AG71476; R25 AG083721-01;"],"award-info":[{"award-number":["R35AG71476; R25 AG083721-01;"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alzheimer&apos;s Disease Drug Discovery Foundation; Ted and Maria Quirk Endowment; Joy Chambers-Grundy Endowment.","id":[{"id":"https:\/\/ror.org\/0229evh14","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RF1NS133812"],"award-info":[{"award-number":["RF1NS133812"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer&apos;s Association","doi-asserted-by":"publisher","award":["ALZDISCOVERY-1051936"],"award-info":[{"award-number":["ALZDISCOVERY-1051936"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56690-4","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:58:14Z","timestamp":1739941094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Drug repurposing for Alzheimer\u2019s disease and other neurodegenerative disorders"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Van Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Cammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7998-939X","authenticated-orcid":false,"given":"Reina","family":"Tonegawa-Kuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7917-5169","authenticated-orcid":false,"given":"Jorge","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1736-2847","authenticated-orcid":false,"given":"Feixiong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"56690_CR1","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"G. B. D. 2019 Dementia Forecasting Collaborators.","year":"2022","unstructured":"G. B. D. 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105\u2013e125 (2022).","journal-title":"Lancet Public Health"},{"key":"56690_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3233\/JAD-220239","volume":"91","author":"A Kenne Malaha","year":"2023","unstructured":"Kenne Malaha, A., Thebaut, C., Achille, D., Preux, P. M. & Guerchet, M. Costs of dementia in low- and middle-income countries: a systematic review. J. Alzheimers Dis. 91, 115\u2013128 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"56690_CR3","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"56690_CR4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S1474-4422(24)00038-3","volume":"23","author":"G. B. D. 2021 Nervous System Disorders Collaborators.","year":"2024","unstructured":"G. B. D. 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 23, 344\u2013381 (2024). (Comprehensive description of the global burden of central nervous system disorders including Alzehimer\u2019s disease).","journal-title":"Lancet Neurol."},{"key":"56690_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings, J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs 83, 569\u2013576 (2023).","journal-title":"Drugs"},{"key":"56690_CR6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3233\/JAD-231318","volume":"98","author":"E Area-Gomez","year":"2024","unstructured":"Area-Gomez, E. & Schon, E. A. Towards a unitary hypothesis of Alzheimer\u2019s disease pathogenesis. J. Alzheimers Dis. 98, 1243\u20131275 (2024).","journal-title":"J. Alzheimers Dis."},{"key":"56690_CR7","first-page":"43","volume":"15","author":"M Nasb","year":"2024","unstructured":"Nasb, M., Tao, W. & Chen, N. Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses. Aging Dis. 15, 43\u201373 (2024).","journal-title":"Aging Dis."},{"key":"56690_CR8","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3233\/JAD-221286","volume":"92","author":"RH Swerdlow","year":"2023","unstructured":"Swerdlow, R. H. The Alzheimer\u2019s disease mitochondrial cascade hypothesis: a current overview. J. Alzheimers Dis. 92, 751\u2013768 (2023).","journal-title":"J. Alzheimers Dis."},{"key":"56690_CR9","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings, J. et al. Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimers Dement 10, e12465 (2024). (Description of all drugs in the Alzheimer\u2019s disease drug development pipeline from Phase 1 to Phase 3).","journal-title":"Alzheimers Dement"},{"key":"56690_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s40258-023-00816-6","volume":"21","author":"KH van der Pol","year":"2023","unstructured":"van der Pol, K. H. et al. Drug repurposing of generic drugs: challenges and the potential role for government. Appl Health Econ. Health Policy 21, 831\u2013840 (2023).","journal-title":"Appl Health Econ. Health Policy"},{"key":"56690_CR11","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.2017.17535","volume":"318","author":"RE Sachs","year":"2017","unstructured":"Sachs, R. E., Ginsburg, P. B. & Goldman, D. P. Encouraging new uses for old drugs. JAMA 318, 2421\u20132422 (2017).","journal-title":"JAMA"},{"key":"56690_CR12","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","volume":"80","author":"D Lee","year":"2023","unstructured":"Lee, D. et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 80, 1307\u20131316 (2023).","journal-title":"JAMA Neurol."},{"key":"56690_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12106","volume":"7","author":"DC Matthews","year":"2021","unstructured":"Matthews, D. C. et al. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer\u2019s dementia. Alzheimers Dement (N. Y) 7, e12106 (2021). (Report of a trial of the repurposed agent, rasagiline, in a clinical trial of Alzheimer\u2019s disease).","journal-title":"Alzheimers Dement (N. Y)"},{"key":"56690_CR14","doi-asserted-by":"publisher","first-page":"e2010372","DOI":"10.1001\/jamanetworkopen.2020.10372","volume":"3","author":"G Koch","year":"2020","unstructured":"Koch, G. et al. Effect of rotigotine vs placebo on cognitive functions among patients with mild to moderate Alzheimer disease: a randomized clinical trial. JAMA Netw. Open 3, e2010372 (2020).","journal-title":"JAMA Netw. Open"},{"key":"56690_CR15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"J Langedijk","year":"2015","unstructured":"Langedijk, J., Mantel-Teeuwisse, A. K., Slijkerman, D. S. & Schutjens, M. H. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov. Today 20, 1027\u20131034 (2015).","journal-title":"Drug Discov. Today"},{"key":"56690_CR16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrd4707","volume":"14","author":"DE Frail","year":"2015","unstructured":"Frail, D. E. et al. Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat. Rev. Drug Discov. 14, 833\u2013841 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"56690_CR17","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000194","volume":"3","author":"GW Beecham","year":"2017","unstructured":"Beecham, G. W. et al. The Alzheimer\u2019s disease sequencing project: study design and sample selection. Neurol. Genet 3, e194 (2017).","journal-title":"Neurol. Genet"},{"key":"56690_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jalz.2011.09.172","volume":"8","author":"MW Weiner","year":"2012","unstructured":"Weiner, M. W. et al. The Alzheimer\u2019s disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement 8, S1\u2013S68 (2012).","journal-title":"Alzheimers Dement"},{"key":"56690_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cphg.105","volume":"108","author":"AK Greenwood","year":"2020","unstructured":"Greenwood, A. K. et al. The AD knowledge portal: a repository for multi-omic data on Alzheimer\u2019s disease and aging. Curr. Protoc. Hum. Genet 108, e105 (2020).","journal-title":"Curr. Protoc. Hum. Genet"},{"key":"56690_CR20","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","volume":"54","author":"C Bellenguez","year":"2022","unstructured":"Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias. Nat. Genet. 54, 412\u2013436 (2022).","journal-title":"Nat. Genet."},{"key":"56690_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41588-020-00776-w","volume":"53","author":"J Schwartzentruber","year":"2021","unstructured":"Schwartzentruber, J. et al. Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer\u2019s disease risk genes. Nat. Genet 53, 392\u2013402 (2021).","journal-title":"Nat. Genet"},{"key":"56690_CR22","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","volume":"51","author":"IE Jansen","year":"2019","unstructured":"Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat. Genet 51, 404\u2013413 (2019). (GWAS demonstrates divese pathways involved in Alzheimer\u2019s disease from a genetic prespective).","journal-title":"Nat. Genet"},{"key":"56690_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101379","volume":"5","author":"F Cheng","year":"2024","unstructured":"Cheng, F. et al. Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer\u2019s disease. Cell Rep. Med 5, 101379 (2024).","journal-title":"Cell Rep. Med"},{"key":"56690_CR24","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s43587-021-00122-7","volume":"1","author":"A Taubes","year":"2021","unstructured":"Taubes, A. et al. Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer\u2019s disease. Nat. Aging 1, 932\u2013947 (2021). (Example of using a combination of experimental and real world data to identify a candidate for repurposing for the treatment of Alzheimer\u2019s disease patients carrying the apolipoprotein gene).","journal-title":"Nat. Aging"},{"key":"56690_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","volume":"20","author":"AD Korczyn","year":"2024","unstructured":"Korczyn, A. D. & Grinberg, L. T. Is Alzheimer\u2019s disease a disease? Nat. Rev. Neurol. 20, 245\u2013251 (2024).","journal-title":"Nat. Rev. Neurol."},{"key":"56690_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13195-020-00760-w","volume":"13","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer\u2019s drug discovery. Alzheimers Res Ther. 13, 24 (2021).","journal-title":"Alzheimers Res Ther."},{"key":"56690_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12350","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. The Alzheimer\u2019s Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer\u2019s disease. Alzheimer\u2019s. Dement. 8, e12350 (2022).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"56690_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39301-y","volume":"14","author":"D Bang","year":"2023","unstructured":"Bang, D., Lim, S., Lee, S. & Kim, S. Biomedical knowledge graph learning for drug repurposing by extending guilt-by-association to multiple layers. Nat. Commun. 14, 3570 (2023).","journal-title":"Nat. Commun."},{"key":"56690_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-023-02757-0","volume":"10","author":"M Boudin","year":"2023","unstructured":"Boudin, M., Diallo, G., Drance, M. & Mougin, F. The OREGANO knowledge graph for computational drug repurposing. Sci. Data 10, 871 (2023).","journal-title":"Sci. Data"},{"key":"56690_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss, S. & Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 58, 323\u2013337 (2005).","journal-title":"J. Clin. Epidemiol."},{"key":"56690_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13195-021-00951-z","volume":"14","author":"J Fang","year":"2022","unstructured":"Fang, J. et al. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer\u2019s disease. Alzheimers Res Ther. 14, 7 (2022). (Use of artificial intelligence as a tool for data exploration and identification of repurposable agents for Alzheimer\u2019s disease).","journal-title":"Alzheimers Res Ther."},{"key":"56690_CR32","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s43587-021-00138-z","volume":"1","author":"J Fang","year":"2021","unstructured":"Fang, J. et al. Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer\u2019s disease. Nat. Aging 1, 1175\u20131188 (2021). (Describes combining in silico network medicine techniques with data from electronic medical records to identify repurposable drugs for Alzheimer\u2019s disease).","journal-title":"Nat. Aging"},{"key":"56690_CR33","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/alz.12819","volume":"19","author":"P Zhang","year":"2023","unstructured":"Zhang, P. et al. Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer\u2019s disease in African Americans. Alzheimers Dement 19, 1876\u20131887 (2023).","journal-title":"Alzheimers Dement"},{"key":"56690_CR34","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"56690_CR35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41746-021-00452-1","volume":"4","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer\u2019s disease. NPJ Digit Med 4, 84 (2021).","journal-title":"NPJ Digit Med"},{"key":"56690_CR36","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/sim.8866","volume":"40","author":"M Webster-Clark","year":"2021","unstructured":"Webster-Clark, M. et al. Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Stat. Med 40, 1718\u20131735 (2021).","journal-title":"Stat. Med"},{"key":"56690_CR37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ijrobp.2020.02.638","volume":"107","author":"N Lalani","year":"2020","unstructured":"Lalani, N., Jimenez, R. B. & Yeap, B. Understanding propensity score analyses. Int J. Radiat. Oncol. Biol. Phys. 107, 404\u2013407 (2020).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"56690_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43929-1","volume":"14","author":"C Zang","year":"2023","unstructured":"Zang, C. et al. High-throughput target trial emulation for Alzheimer\u2019s disease drug repurposing with real-world data. Nat. Commun. 14, 8180 (2023). (Describes the techniques involved in trial simulation to conduct virtual trials in medical record populations to determine the likely outcome of similarly peformed real world clinical trials).","journal-title":"Nat. Commun."},{"key":"56690_CR39","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","volume":"74","author":"HH Feldman","year":"2010","unstructured":"Feldman, H. H. et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956\u2013964 (2010).","journal-title":"Neurology"},{"key":"56690_CR40","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46, D1074\u2013d1082 (2018).","journal-title":"Nucleic Acids Res"},{"key":"56690_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10744-6","volume":"10","author":"F Cheng","year":"2019","unstructured":"Cheng, F. et al. A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat. Commun. 10, 3476 (2019).","journal-title":"Nat. Commun."},{"key":"56690_CR42","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1101\/gr.272484.120","volume":"31","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Multimodal single-cell\/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer\u2019s disease. Genome Res 31, 1900\u20131912 (2021).","journal-title":"Genome Res"},{"key":"56690_CR43","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1002\/med.21709","volume":"40","author":"J Fang","year":"2020","unstructured":"Fang, J. et al. Harnessing endophenotypes and network medicine for Alzheimer\u2019s drug repurposing. Med Res Rev. 40, 2386\u20132426 (2020).","journal-title":"Med Res Rev."},{"key":"56690_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbi.2014.03.014","volume":"51","author":"F Wang","year":"2014","unstructured":"Wang, F., Zhang, P., Cao, N., Hu, J. & Sorrentino, R. Exploring the associations between drug side-effects and therapeutic indications. J. Biomed. Inf. 51, 15\u201323 (2014).","journal-title":"J. Biomed. Inf."},{"key":"56690_CR45","doi-asserted-by":"publisher","unstructured":"Froldi, G. View on metformin: antidiabetic and pleiotropic effects, pharmacokinetics, side effects, and sex-related differences. Pharmaceuticals (Basel) 17. https:\/\/doi.org\/10.3390\/ph17040478 (2024).","DOI":"10.3390\/ph17040478"},{"key":"56690_CR46","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1093\/brain\/awad161","volume":"146","author":"MJ Koretsky","year":"2023","unstructured":"Koretsky, M. J. et al. Genetic risk factor clustering within and across neurodegenerative diseases. Brain 146, 4486\u20134494 (2023).","journal-title":"Brain"},{"key":"56690_CR47","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/jnnp-2017-316988","volume":"89","author":"GK Tofaris","year":"2018","unstructured":"Tofaris, G. K. & Buckley, N. J. Convergent molecular defects underpin diverse neurodegenerative diseases. J. Neurol. Neurosurg. Psychiatry 89, 962\u2013969 (2018).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"56690_CR48","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1093\/brain\/awab222","volume":"144","author":"DC Matthews","year":"2021","unstructured":"Matthews, D. C. et al. Riluzole, a glutamate modulator, slows cerebral glucose metabolism decline in patients with Alzheimer\u2019s disease. Brain 144, 3742\u20133755 (2021).","journal-title":"Brain"},{"key":"56690_CR49","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00702-018-1853-9","volume":"125","author":"E Szoko","year":"2018","unstructured":"Szoko, E., Tabi, T., Riederer, P., Vecsei, L. & Magyar, K. Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson\u2019s disease. J. Neural Transm. (Vienna) 125, 1735\u20131749 (2018).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"56690_CR50","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/mp.2016.33","volume":"22","author":"AC Pereira","year":"2017","unstructured":"Pereira, A. C. et al. Age and Alzheimer\u2019s disease gene expression profiles reversed by the glutamate modulator riluzole. Mol. Psychiatry 22, 296\u2013305 (2017).","journal-title":"Mol. Psychiatry"},{"key":"56690_CR51","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1038\/npp.2014.119","volume":"39","author":"G Koch","year":"2014","unstructured":"Koch, G. et al. Dopaminergic modulation of cortical plasticity in Alzheimer\u2019s disease patients. Neuropsychopharmacology 39, 2654\u20132661 (2014).","journal-title":"Neuropsychopharmacology"},{"key":"56690_CR52","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/ana.22093","volume":"68","author":"EP Pioro","year":"2010","unstructured":"Pioro, E. P. et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann. Neurol. 68, 693\u2013702 (2010). (Report of a clinical trial of a drug combination for repurposed agents for the treatment of pseudobulbar affect).","journal-title":"Ann. Neurol."},{"key":"56690_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0555-x","volume":"9","author":"G Williams","year":"2019","unstructured":"Williams, G. et al. Drug repurposing for Alzheimer\u2019s disease based on transcriptional profiling of human iPSC-derived cortical neurons. Transl. Psychiatry 9, 220 (2019).","journal-title":"Transl. Psychiatry"},{"key":"56690_CR54","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/brain\/awac136","volume":"146","author":"G Oliveros","year":"2023","unstructured":"Oliveros, G. et al. Repurposing ibudilast to mitigate Alzheimer\u2019s disease by targeting inflammation. Brain 146, 898\u2013911 (2023).","journal-title":"Brain"},{"key":"56690_CR55","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.cell.2021.03.032","volume":"184","author":"MK Shin","year":"2021","unstructured":"Shin, M. K. et al. Reducing acetylated tau is neuroprotective in brain injury. Cell 184, 2715\u20132732.e2723 (2021).","journal-title":"Cell"},{"key":"56690_CR56","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/mdc3.12940","volume":"7","author":"L VandeVrede","year":"2020","unstructured":"VandeVrede, L. et al. Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy. Mov. Disord. Clin. Pr. 7, 440\u2013447 (2020).","journal-title":"Mov. Disord. Clin. Pr."},{"key":"56690_CR57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/alz.12450","volume":"18","author":"JL Cummings","year":"2022","unstructured":"Cummings, J. L., Goldman, D. P., Simmons-Stern, N. R. & Ponton, E. The costs of developing treatments for Alzheimer\u2019s disease: A retrospective exploration. Alzheimers Dement 18, 469\u2013477 (2022).","journal-title":"Alzheimers Dement"},{"key":"56690_CR58","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JAD-179901","volume":"64","author":"J Cummings","year":"2018","unstructured":"Cummings, J., Ritter, A. & Zhong, K. Clinical trials for disease-modifying therapies in Alzheimer\u2019s disease: a primer, lessons learned, and a blueprint for the future. J. Alzheimers Dis. 64, S3\u2013S22 (2018).","journal-title":"J. Alzheimers Dis."},{"key":"56690_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/2042098619865413","volume":"10","author":"N Raj","year":"2019","unstructured":"Raj, N. et al. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Ther. Adv. Drug Saf. 10, 2042098619865413 (2019).","journal-title":"Ther. Adv. Drug Saf."},{"key":"56690_CR60","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/wsbm.147","volume":"3","author":"SN Deftereos","year":"2011","unstructured":"Deftereos, S. N., Andronis, C., Friedla, E. J., Persidis, A. & Persidis, A. Drug repurposing and adverse event prediction using high-throughput literature analysis. Wiley Interdiscip. Rev. Syst. Biol. Med 3, 323\u2013334 (2011).","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med"},{"key":"56690_CR61","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.therap.2020.02.006","volume":"75","author":"C Fetro","year":"2020","unstructured":"Fetro, C. & Scherman, D. Drug repurposing in rare diseases: Myths and reality. Therapie 75, 157\u2013160 (2020).","journal-title":"Therapie"},{"key":"56690_CR62","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40258-021-00705-w","volume":"20","author":"NX Nguyen","year":"2022","unstructured":"Nguyen, N. X., Sheingold, S. H., Tarazi, W. & Bosworth, A. Effect of competition on generic drug prices. Appl Health Econ. Health Policy 20, 243\u2013253 (2022).","journal-title":"Appl Health Econ. Health Policy"},{"key":"56690_CR63","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019). (Review of the opportunities and challenges for repurposed drug development).","journal-title":"Nat. Rev. Drug Discov."},{"key":"56690_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08272-z","volume":"22","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy, N., Grimshaw, A. A., Axson, S. A., Choe, S. H. & Miller, J. E. Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv. Res 22, 970 (2022).","journal-title":"BMC Health Serv. Res"},{"key":"56690_CR65","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ddstr.2011.10.002","volume":"8","author":"TI Oprea","year":"2011","unstructured":"Oprea, T. I. et al. Drug repurposing from an academic perspective. Drug Discov. Today Ther. Strateg 8, 61\u201369 (2011).","journal-title":"Drug Discov. Today Ther. Strateg"},{"key":"56690_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02790-7","volume":"18","author":"LJ Fermaglich","year":"2023","unstructured":"Fermaglich, L. J. & Miller, K. L. A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act. Orphanet J. Rare Dis. 18, 163 (2023). (Description of incentive used in the developing orphan drugs for rare diseases).","journal-title":"Orphanet J. Rare Dis."},{"key":"56690_CR67","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21250","author":"JC Robinson","year":"2022","unstructured":"Robinson, J. C. An innovation surcharge to fund the repurposing of generic drugs. JAMA https:\/\/doi.org\/10.1001\/jama.2022.21250 (2022).","journal-title":"JAMA"},{"key":"56690_CR68","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/acn3.76","volume":"1","author":"DW Shineman","year":"2014","unstructured":"Shineman, D. W. et al. Overcoming obstacles to repurposing for neurodegenerative disease. Ann. Clin. Transl. Neurol. 1, 512\u2013518 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"56690_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1387517","volume":"11","author":"EL Spin","year":"2024","unstructured":"Spin, E. L., Mantel-Teeuwisse, A. K. & Pasmooij, A. M. G. International regulatory and publicly-funded initiatives to advance drug repurposing. Front Med (Lausanne) 11, 1387517 (2024).","journal-title":"Front Med (Lausanne)"},{"key":"56690_CR70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fphar.2017.00729","volume":"8","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y., Tagawa, M., Ito, H., Tsuruma, K. & Hara, H. Overcoming obstacles to drug repositioning in Japan. Front Pharm. 8, 729 (2017).","journal-title":"Front Pharm."},{"key":"56690_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.817663","volume":"8","author":"C Asker-Hagelberg","year":"2021","unstructured":"Asker-Hagelberg, C. et al. Repurposing of medicines in the EU: launch of a pilot framework. Front Med (Lausanne) 8, 817663 (2021).","journal-title":"Front Med (Lausanne)"},{"key":"56690_CR72","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.drudis.2015.12.004","volume":"21","author":"V Montazerhodjat","year":"2016","unstructured":"Montazerhodjat, V., Frishkopf, J. J. & Lo, A. W. Financing drug discovery via dynamic leverage. Drug Discov. Today 21, 410\u2013414 (2016).","journal-title":"Drug Discov. Today"},{"key":"56690_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05273-x","volume":"22","author":"C Verbaanderd","year":"2021","unstructured":"Verbaanderd, C., Rooman, I. & Huys, I. Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research. Trials 22, 322 (2021). (Discussion of novel funding pathways for development of repusposed agents).","journal-title":"Trials"},{"key":"56690_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2020.102332","volume":"72","author":"GT Sanzenbacher","year":"2020","unstructured":"Sanzenbacher, G. T. & Wettstein, G. Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D. J. Health Econ. 72, 102332 (2020).","journal-title":"J. Health Econ."},{"key":"56690_CR75","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","volume":"72","author":"JP Jourdan","year":"2020","unstructured":"Jourdan, J. P., Bureau, R., Rochais, C. & Dallemagne, P. Drug repositioning: a brief overview. J. Pharm. Pharm. 72, 1145\u20131151 (2020).","journal-title":"J. Pharm. Pharm."},{"key":"56690_CR76","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/d41573-021-00090-y","volume":"20","author":"CP Austin","year":"2021","unstructured":"Austin, C. P., Mount, B. A. & Colvis, C. M. Envisioning an actionable research agenda to facilitate repurposing of off-patent drugs. Nat. Rev. Drug Discov. 20, 723\u2013724 (2021). (Discussion of how stakeholders might collaborate to advance repurposed drug development).","journal-title":"Nat. Rev. Drug Discov."},{"key":"56690_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-023-01639-x","author":"DT Michaeli","year":"2023","unstructured":"Michaeli, D. T., Michaeli, T., Albers, S., Boch, T. & Michaeli, J. C. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur. J. Health Econ. https:\/\/doi.org\/10.1007\/s10198-023-01639-x (2023).","journal-title":"Eur. J. Health Econ."},{"key":"56690_CR78","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"JJ Hernandez","year":"2017","unstructured":"Hernandez, J. J. et al. Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 7, 273 (2017).","journal-title":"Front Oncol."},{"key":"56690_CR79","doi-asserted-by":"crossref","unstructured":"Cummings, J., Kinney, J. & Fillit, H. In Alzheimer\u2019s drug development: a research and development ecosystem (eds J. Cummings, J. Kinney, & H. Fillit) 1-24 (Cambridge University Press, 2022).","DOI":"10.1017\/9781108975759.002"},{"key":"56690_CR80","doi-asserted-by":"publisher","first-page":"e2336470","DOI":"10.1001\/jamanetworkopen.2023.36470","volume":"6","author":"PA Harris","year":"2023","unstructured":"Harris, P. A. et al. Leveraging the expertise of the CTSA program to increase the impact and efficiency of clinical trials. JAMA Netw. Open 6, e2336470 (2023).","journal-title":"JAMA Netw. Open"},{"key":"56690_CR81","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2020.00282","volume":"11","author":"PD Stonier","year":"2020","unstructured":"Stonier, P. D. et al. Evolution of the development of core competencies in pharmaceutical medicine and their potential use in education and training. Front Pharm. 11, 282 (2020).","journal-title":"Front Pharm."},{"key":"56690_CR82","doi-asserted-by":"publisher","first-page":"113","DOI":"10.14283\/jpad.2021.49","volume":"9","author":"AR Shaw","year":"2022","unstructured":"Shaw, A. R. et al. Representation of racial and ethnic minority populations in dementia prevention trials: a systematic review. J. Prev. Alzheimers Dis. 9, 113\u2013118 (2022). (Discussion of the low rate of inclusions of participants from under-represented groups in Alzheimer\u2019s disease clinical trials and strategies for mitiating the challenges).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"56690_CR83","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res"},{"key":"56690_CR84","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen, W. G., Mohs, R. C. & Davis, K. L. A new rating scale for Alzheimer\u2019s disease. Am. J. Psychiatry 141, 1356\u20131364 (1984).","journal-title":"Am. J. Psychiatry"},{"key":"56690_CR85","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","volume":"11","author":"D Galasko","year":"1997","unstructured":"Galasko, D. et al. An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 11, S33\u2013S39 (1997).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"56690_CR86","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings, J. L. et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308\u20132314 (1994).","journal-title":"Neurology"},{"key":"56690_CR87","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1192\/bjp.140.6.566","volume":"140","author":"CP Hughes","year":"1982","unstructured":"Hughes, C. P., Berg, L., Danziger, W. L., Coben, L. A. & Martin, R. L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 140, 566\u2013572 (1982).","journal-title":"Br. J. Psychiatry"},{"key":"56690_CR88","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0070-2153(05)70008-9","volume":"70","author":"C Wu","year":"2005","unstructured":"Wu, C., Pike, V. W. & Wang, Y. Amyloid imaging: from benchtop to bedside. Curr. Top. Dev. Biol. 70, 171\u2013213 (2005).","journal-title":"Curr. Top. Dev. Biol."},{"key":"56690_CR89","doi-asserted-by":"crossref","unstructured":"Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J. Alzheimers Dis. 34, 457\u2013468 (2013).","DOI":"10.3233\/JAD-122059"},{"key":"56690_CR90","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/alz.12618","volume":"18","author":"H Zetterberg","year":"2022","unstructured":"Zetterberg, H. Biofluid-based biomarkers for Alzheimer\u2019s disease-related pathologies: An update and synthesis of the literature. Alzheimers Dement 18, 1687\u20131693 (2022).","journal-title":"Alzheimers Dement"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56690-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56690-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56690-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:58:24Z","timestamp":1739941104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56690-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56690"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56690-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C. has provided consultation to Acadia, Acumen, ALZpath, Axsome\u00a0Artery, Biogen, Biohaven, Bristol-Myers Squib, Eisai, Fosun, GAP Foundation, Janssen, Karuna, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP\/eqt, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, Optoceutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, sinaptica, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies. J.C. is the owner of the Neuropsychiatric Inventory. Y.Z., A.S., D.C., R.T.-K., J.F., and F.C. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1755"}}